Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

839 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V. Engert A, et al. Among authors: diehl v. N Engl J Med. 2010 Aug 12;363(7):640-52. doi: 10.1056/NEJMoa1000067. N Engl J Med. 2010. PMID: 20818855 Free article. Clinical Trial.
First-line treatment of Hodgkin's lymphoma.
Klimm B, Engert A, Diehl V. Klimm B, et al. Among authors: diehl v. Curr Hematol Rep. 2005 Jan;4(1):15-22. Curr Hematol Rep. 2005. PMID: 15610655 Review.
Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
Eich HT, Haverkamp U, Engert A, Kocher M, Skripnitchenko R, Brillant C, Sehlen S, Dühmke E, Diehl V, Müller RP. Eich HT, et al. Among authors: diehl v. Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):860-5. doi: 10.1016/j.ijrobp.2005.02.053. Epub 2005 May 31. Int J Radiat Oncol Biol Phys. 2005. PMID: 15925455 Clinical Trial.
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, Herrmann R, Pfreundschuh M, Sieber M, Tesch H, Franke A, Koch P, de Wit M, Paulus U, Hasenclever D, Loeffler M, Müller RP, Müller-Hermelink HK, Dühmke E, Diehl V. Engert A, et al. Among authors: diehl v. J Clin Oncol. 2007 Aug 10;25(23):3495-502. doi: 10.1200/JCO.2006.07.0482. Epub 2007 Jul 2. J Clin Oncol. 2007. PMID: 17606976 Clinical Trial.
Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Diehl V, Fuchs M; GHSG. Diehl V, et al. Transfus Apher Sci. 2007 Aug;37(1):37-41. doi: 10.1016/j.transci.2007.04.004. Epub 2007 Aug 21. Transfus Apher Sci. 2007. PMID: 17714996 Review.
MOPP and/or ABVD and furthermore the alternating MOPP/ABVD or the MOPP/ABV hybrid with and without the help of consolidative radiation resulted in around 70% long term survival rates, 30-40% of patients experienced tumor progression or relapses within 5 years. This led the German …
MOPP and/or ABVD and furthermore the alternating MOPP/ABVD or the MOPP/ABV hybrid with and without the help of consolidative radiation resul …
839 results